Singapore markets closed

Sorrento Therapeutics, Inc. (SRNE)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.0200-0.0040 (-16.67%)
At close: 03:56PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 13.23M
Enterprise value 140.20M
Trailing P/E N/A
Forward P/E 1.10
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.19
Price/book (mrq)N/A
Enterprise value/revenue 2.18
Enterprise value/EBITDA -0.26

Trading information

Stock price history

Beta (5Y monthly) 2.29
52-week change 3-92.87%
S&P500 52-week change 321.23%
52-week high 30.4190
52-week low 30.0006
50-day moving average 30.0221
200-day moving average 30.0985

Share statistics

Avg vol (3-month) 3355.49k
Avg vol (10-day) 3367.19k
Shares outstanding 5551.28M
Implied shares outstanding 6551.28M
Float 8538.99M
% held by insiders 10.89%
% held by institutions 10.07%
Shares short (31 Jan 2023) 464.56M
Short ratio (31 Jan 2023) 44.96
Short % of float (31 Jan 2023) 411.96%
Short % of shares outstanding (31 Jan 2023) 411.84%
Shares short (prior month 30 Dec 2022) 461.44M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:25
Last split date 301 Aug 2013

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2022
Most-recent quarter (mrq)30 Jun 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)-510.93%

Management effectiveness

Return on assets (ttm)-40.81%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)64.27M
Revenue per share (ttm)0.13
Quarterly revenue growth (yoy)31.10%
Gross profit (ttm)N/A
EBITDA -341.59M
Net income avi to common (ttm)-548M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)80.64M
Total cash per share (mrq)0.15
Total debt (mrq)207.6M
Total debt/equity (mrq)N/A
Current ratio (mrq)0.41
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-234.63M
Levered free cash flow (ttm)-57.53M